On April 27, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting on June 2-6, 2023, in Chicago, Illinois (Press release, Compugen, APR 27, 2023, View Source [SID1234630637]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer
Abstract Number: 5595
Session Title: Gynecologic Cancer
Lead Author: Rasco, D, MD
Date: Monday, June 5, 2023